Complete Filing Data
Longeveron Inc. reported Stockholders Equity of $5.68 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Longeveron Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$22.7M | -$16.0M | -$21.4M | -$18.8M | -$17.0M | -$3.7M |
| Revenue * | $1.2M | $2.4M | $709.0K | $940.0K | $708.0K | $55.0K |
| Research And Development Expense | $12.0M | $8.1M | $9.1M | $9.4M | $7.1M | $2.7M |
| Operating Income Loss | -$23.3M | -$16.5M | -$21.0M | -$18.0M | -$17.5M | -$3.8M |
| Operating Expenses | $24.1M | $18.4M | $21.3M | $18.5M | $18.0M | $5.6M |
| Gross Profit | $803.0K | $1.9M | $221.0K | $497.0K | $590.0K | $1.8M |
| General And Administrative Expense | $12.0M | $10.3M | $12.2M | $8.1M | $9.7M | $2.7M |
| Cost Of Revenue | $396.0K | $508.0K | $488.0K | $725.0K | $716.0K | $3.8M |
| Other Nonoperating Income Expense | $680.0K | $549.0K | -$377.0K | $300.0K | $411.0K | $57.0K |
| Selling And Marketing Expense | $783.0K | $1.1M | $1.2M | $199.0K | ||
| Comprehensive Income Net Of Tax | -$21.4M | -$19.2M | -$17.0M | |||
| Nonoperating Income Expense | $583.0K | $549.0K | -$384.0K | -$792.0K | ||
| Net Income Loss Available To Common Stockholders Basic | -$22.7M | -$24.6M | -$22.2M | -$18.8M | ||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$18.8M | -$17.0M | -$3.7M | |||
| Deferred Revenue | $10.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$7.2M | -$5.0M | -$5.0M | -$4.4M | -$3.4M | -$4.1M | -$5.1M | -$5.6M | -$4.6M | -$5.2M | -$5.6M | -$3.5M | -$4.9M | -$5.0M | -$3.1M | -$938.0K | -$1.2M | -$213.0K | |
| Revenue * | $137.0K | $316.0K | $381.0K | $773.0K | $468.0K | $548.0K | $150.0K | $217.0K | $238.0K | $265.0K | $340.0K | $310.0K | $232.0K | $489.0K | $376.0K | $47.0K | $8.0K | $1.7M | |
| Research And Development Expense | $3.9M | $3.0M | $2.5M | $2.2M | $1.7M | $2.2M | $1.8M | $2.3M | $2.8M | $3.0M | $1.7M | $1.3M | $2.0M | $2.0M | $1.4M | $585.0K | $642.0K | $289.0K | |
| Operating Income Loss | -$7.3M | -$5.4M | -$5.2M | -$4.6M | -$3.5M | -$4.1M | -$5.2M | -$5.7M | -$4.7M | -$5.2M | -$4.2M | -$3.4M | -$4.9M | -$5.1M | -$3.5M | -$958.0K | -$1.2M | -$213.0K | |
| Operating Expenses | $7.4M | $5.5M | $5.5M | $5.3M | $3.8M | $4.4M | $5.2M | $5.8M | $4.8M | $5.3M | $4.4M | $3.6M | $5.1M | $5.3M | $3.6M | $1.3M | $1.3M | $1.0M | |
| Gross Profit | $125.0K | $146.0K | $275.0K | $682.0K | $344.0K | $329.0K | $54.0K | $93.0K | $76.0K | $92.0K | $160.0K | $165.0K | $164.0K | $208.0K | $149.0K | $373.0K | $112.0K | $812.0K | |
| General And Administrative Expense | $3.6M | $2.6M | $2.9M | $3.1M | $2.1M | $2.2M | $3.4M | $3.5M | $2.0M | $2.1M | $2.4M | $2.0M | $3.0M | $3.3M | $1.7M | $702.0K | $649.0K | $686.0K | |
| Cost Of Revenue | $12.0K | $170.0K | $106.0K | $91.0K | $124.0K | $219.0K | $96.0K | $124.0K | $203.0K | $173.0K | $306.0K | $205.0K | $68.0K | $281.0K | $227.0K | $1.5M | $764.0K | $896.0K | |
| Other Nonoperating Income Expense | $89.0K | $369.0K | $170.0K | $230.0K | $87.0K | $32.0K | $55.0K | $80.0K | $69.0K | -$57.0K | -$1.4M | -$116.0K | $50.0K | $52.0K | $347.0K | $20.0K | $10.0K | ||
| Selling And Marketing Expense | $280.0K | $143.0K | $157.0K | $245.0K | $234.0K | $287.0K | $25.0K | $53.0K | $550.0K | $44.0K | $47.0K | $50.0K | |||||||
| Comprehensive Income Net Of Tax | -$7.2M | -$5.0M | -$5.0M | -$4.4M | -$3.4M | -$4.1M | -$5.1M | -$5.7M | -$4.6M | -$5.2M | -$5.6M | -$3.5M | |||||||
| Nonoperating Income Expense | $89.0K | $369.0K | $170.0K | $230.0K | $87.0K | $32.0K | $55.0K | $80.0K | $69.0K | -$1.4M | |||||||||
| Net Income Loss Available To Common Stockholders Basic | -$7.2M | -$5.0M | -$4.6M | -$11.9M | -$5.9M | -$5.6M | -$5.2M | ||||||||||||
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | -$5.6M | -$4.6M | -$5.2M | -$5.6M | -$3.5M | -$4.9M | -$5.0M | -$3.1M | -$938.0K | ||||||||||
| Deferred Revenue | $505.0K | $520.0K | $505.0K | $199.0K | $202.0K | $230.0K | $385.0K | $200.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $5.7M | $21.9M | $6.7M | $20.5M | $37.5M | $2.0M | $4.4K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $4.7M | $19.2M | $4.9M | $10.5M | $25.7M | $816.0K | $1.9M |
| Cash And Cash Equivalents At Carrying Value | $4.7M | $19.2M | $4.9M | $10.5M | $25.7M | $816.0K | |
| Property Plant And Equipment Net | $1.8M | $2.4M | $2.5M | $2.9M | $3.1M | $3.6M | |
| Prepaid Expense And Other Assets Current | $686.0K | $308.0K | $376.0K | $404.0K | $282.0K | $52.0K | |
| Liabilities Current | $4.1M | $2.6M | $3.9M | $4.9M | $2.7M | $3.8M | |
| Liabilities And Stockholders Equity | $10.3M | $25.6M | $12.1M | $27.4M | $42.8M | $9.2M | |
| Liabilities | $4.6M | $3.7M | $5.3M | $6.9M | $5.3M | $7.3M | |
| Intangible Assets Net Excluding Goodwill | $2.3M | $2.4M | $2.3M | $2.4M | $2.3M | $1.5M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$14.6M | $14.3M | -$5.6M | -$15.2M | $24.8M | -$1.1M | |
| Assets Current | $5.5M | $19.6M | $5.8M | $20.3M | $35.4M | $1.8M | |
| Assets | $10.3M | $25.6M | $12.1M | $27.4M | $42.8M | $9.2M | |
| Accrued Liabilities Current | $3.0M | $1.8M | $2.2M | $650.0K | $1.3M | $1.5M | |
| Retained Earnings Accumulated Deficit | -$132.3M | -$109.6M | -$85.0M | -$62.8M | -$43.9M | ||
| Accounts Payable Current | $423.0K | $99.0K | $638.0K | $1.8M | $1.6M | ||
| Operating Lease Right Of Use Asset | $513.0K | $882.0K | $1.2M | $1.5M | $1.8M | ||
| Operating Lease Liability Current | $655.0K | $623.0K | $593.0K | $564.0K | $537.0K | $511.0K | |
| Accounts Receivable Net Current | $104.0K | $84.0K | $111.0K | $218.0K | $55.0K | ||
| Stock Issued During Period Class A Common Stock Held For Taxes On RS Us Vested | -$311.0K | -$349.0K | -$174.0K | -$304.0K | |||
| Other Assets | $177.0K | $177.0K | |||||
| Operating Lease Liability Noncurrent | $169.0K | $824.0K | $1.4M | $2.0M | |||
| Liabilities Noncurrent | $499.0K | $1.1M | $1.4M | $2.0M | |||
| Loans Payable Current | $537.0K | $139.0K | |||||
| Other Assets Noncurrent | $176.0K | $202.0K | $193.0K | $244.0K | |||
| Increase Decrease Lease Liability | $197.0K | $254.0K | $261.0K | ||||
| Debt And Capital Lease Obligations | $2.6M | $3.5M | |||||
| Treasury Stock Value | $100.0K | ||||||
| Lease Liability | $2.6M | $3.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $10.0M | $12.7M | $17.2M | $25.6M | $14.9M | $3.0M | $6.6M | $11.3M | $16.3M | $24.6M | $29.4M | $34.3M | $22.3M | $24.7M | $26.5M | $3.3M | $4.2M | $5.4M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $9.2M | $10.3M | $14.3M | $22.8M | $12.4M | $1.9M | $2.0M | $2.7M | $5.0M | $13.6M | $20.2M | $22.1M | $9.7M | $16.8M | $24.5M | ||||||
| Cash And Cash Equivalents At Carrying Value | $9.2M | $10.3M | $14.3M | $22.8M | $12.4M | $1.9M | $2.0M | $2.7M | $1.9M | $9.7M | $16.8M | $24.5M | $1.4M | $1.7M | $2.5M | $1.9M | |||||
| Property Plant And Equipment Net | $2.1M | $2.3M | $2.3M | $2.6M | $2.4M | $2.3M | $2.5M | $2.7M | $2.8M | $3.1M | $2.8M | $3.0M | $3.1M | $3.2M | $3.4M | ||||||
| Prepaid Expense And Other Assets Current | $1.0M | $904.0K | $919.0K | $609.0K | $817.0K | $1.3M | $1.0M | $1.5M | $1.1M | $744.0K | $1.0M | $1.2M | $524.0K | $593.0K | $836.0K | ||||||
| Liabilities Current | $4.9M | $3.3M | $2.7M | $3.1M | $3.2M | $5.3M | $3.4M | $4.1M | $3.6M | $3.7M | $3.6M | $2.4M | $1.9M | $2.2M | $2.8M | ||||||
| Liabilities And Stockholders Equity | $15.6M | $16.7M | $20.8M | $29.9M | $19.4M | $9.7M | $11.6M | $17.1M | $21.8M | $30.5M | $35.3M | $39.2M | $27.2M | $29.9M | $32.4M | ||||||
| Liabilities | $5.6M | $4.1M | $3.7M | $4.3M | $4.5M | $6.7M | $5.0M | $5.8M | $5.5M | $5.9M | $5.9M | $4.9M | $4.8M | $5.2M | $5.9M | ||||||
| Intangible Assets Net Excluding Goodwill | $2.3M | $2.3M | $2.3M | $2.3M | $2.4M | $2.3M | $2.5M | $2.5M | $2.4M | $2.4M | $2.4M | $2.4M | $2.4M | $2.4M | $1.5M | ||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$4.9M | -$3.0M | -$5.5M | -$3.5M | $23.6M | $612.0K | |||||||||||||||
| Assets Current | $10.3M | $11.3M | $15.3M | $23.8M | $13.4M | $3.8M | $5.0M | $10.3M | $14.9M | $23.2M | $28.2M | $31.9M | $19.7M | $22.1M | $25.3M | ||||||
| Assets | $15.6M | $16.7M | $20.8M | $29.9M | $19.4M | $9.7M | $11.6M | $17.1M | $21.8M | $30.5M | $35.3M | $39.2M | $27.2M | $29.9M | $32.4M | ||||||
| Accrued Liabilities Current | $3.2M | $1.9M | $1.6M | $1.5M | $1.6M | $2.4M | $1.5M | $1.3M | $613.0K | $728.0K | $823.0K | $791.0K | $834.0K | $1.3M | $961.0K | ||||||
| Retained Earnings Accumulated Deficit | -$126.9M | -$119.6M | -$114.6M | -$105.5M | -$101.0M | -$89.0M | -$79.0M | -$73.1M | -$89.0M | -$58.3M | -$53.1M | -$47.4M | -$39.9M | -$35.0M | -$30.0M | ||||||
| Accounts Payable Current | $1.1M | $700.0K | $367.0K | $887.0K | $600.0K | $1.5M | $829.0K | $1.7M | $527.0K | $327.0K | $561.0K | $645.0K | $361.0K | $149.0K | $895.0K | ||||||
| Operating Lease Right Of Use Asset | $608.0K | $701.0K | $793.0K | $970.0K | $1.1M | $1.1M | $1.3M | $1.4M | $1.5M | $1.6M | |||||||||||
| Operating Lease Liability Current | $647.0K | $639.0K | $631.0K | $616.0K | $608.0K | $601.0K | $530.0K | $524.0K | $517.0K | ||||||||||||
| Accounts Receivable Net Current | $52.0K | $31.0K | $29.0K | $380.0K | $218.0K | $178.0K | $96.0K | $96.0K | $96.0K | ||||||||||||
| Stock Issued During Period Class A Common Stock Held For Taxes On RS Us Vested | -$133.0K | -$58.0K | -$270.0K | -$5.0K | -$21.0K | -$50.0K | -$86.0K | -$17.0K | |||||||||||||
| Other Assets | $197.0K | $223.0K | $247.0K | $244.0K | $237.0K | $219.0K | $234.0K | $177.0K | $177.0K | $177.0K | |||||||||||
| Operating Lease Liability Noncurrent | $336.0K | $501.0K | $664.0K | $983.0K | $1.1M | $1.3M | $1.6M | $1.7M | |||||||||||||
| Liabilities Noncurrent | $651.0K | $809.0K | $966.0K | $1.2M | $1.3M | $1.4M | $1.6M | $1.7M | |||||||||||||
| Loans Payable Current | $586.0K | $578.0K | $571.0K | $564.0K | $557.0K | $550.0K | $543.0K | $5.0K | $5.0K | $4.0K | |||||||||||
| Other Assets Noncurrent | $178.0K | $200.0K | $201.0K | $203.0K | $204.0K | $190.0K | |||||||||||||||
| Increase Decrease Lease Liability | $76.0K | $64.0K | $63.0K | $65.0K | |||||||||||||||||
| Debt And Capital Lease Obligations | $1.9M | $2.0M | $2.2M | $2.3M | $2.5M | $2.9M | $3.0M | $3.2M | |||||||||||||
| Treasury Stock Value | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | |||||||||||||
| Lease Liability | $1.9M | $2.0M | $2.3M | $2.5M | $2.7M | $2.9M | $3.0M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$18.6M | -$13.9M | -$19.0M | -$14.0M | -$9.6M | -$2.4M |
| Net Cash Provided By Used In Financing Activities | $4.7M | $28.8M | $5.3M | -$509.0K | $45.2M | $1.6M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $378.0K | -$68.0K | -$28.0K | $122.0K | $227.0K | -$2.0K |
| Increase Decrease In Accrued Liabilities | $1.3M | -$332.0K | $1.5M | -$677.0K | -$214.0K | $1.0M |
| Increase Decrease In Accounts Payable | $325.0K | -$540.0K | -$1.1M | $1.1M | -$945.0K | $131.0K |
| Increase Decrease In Accounts And Other Receivables | $20.0K | -$27.0K | -$107.0K | $164.0K | -$366.0K | -$31.0K |
| Payments To Acquire Intangible Assets | $350.0K | $337.0K | $393.0K | $287.0K | $980.0K | $130.0K |
| Net Cash Provided By Used In Investing Activities | -$595.0K | -$640.0K | $8.2M | -$677.0K | -$10.7M | -$261.0K |
| Payments To Acquire Property Plant And Equipment | $245.0K | $655.0K | $301.0K | $569.0K | $330.0K | $131.0K |
| Increase Decrease In Other Operating Assets | -$25.0K | $9.0K | -$51.0K | $15.0K | $4.0K | -$74.0K |
| Stock Issued During Period Value Share Based Compensation | $1.7M | $2.3M | $2.3M | $6.4M | $39.0K | |
| Share Based Compensation | $1.7M | $2.3M | $2.0M | $2.2M | $1.3M | $44.0K |
| Employee Benefits And Share Based Compensation | $2.2M | $6.4M | $39.0K | |||
| Payments Of Stock Issuance Costs | $1.2M | $2.1M | $1.2M | $3.0M | ||
| Depreciation Amortization And Accretion Net | $893.0K | $914.0K | $785.0K | |||
| Increase Decrease In Deferred Revenue | $0.00 | -$466.0K | $307.0K | |||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $2.3M | $2.0M | $2.3M | |||
| Proceeds From Issuance Of Common Stock | $5.0M | $12.9M | $5.3M | $2.0K | $26.7M | |
| Payments Related To Tax Withholding For Share Based Compensation | $174.0K | $304.0K | $451.0K | |||
| Increase Decrease In Other Operating Capital Net | $254.0K | $254.0K | $254.0K | |||
| Proceeds From Sale And Maturity Of Marketable Securities | $0.00 | $352.0K | $8.9M | $179.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$4.7M | -$3.1M | -$5.8M | -$4.2M | -$3.0M | -$398.0K | ||||||||||||
| Net Cash Provided By Used In Financing Activities | -$58.0K | $63.0K | -$17.0K | -$141.0K | $26.7M | $1.2M | ||||||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $610.0K | $912.0K | $694.0K | $908.0K | $785.0K | $45.0K | ||||||||||||
| Increase Decrease In Accrued Liabilities | -$172.0K | $249.0K | -$38.0K | -$604.0K | -$503.0K | $7.0K | ||||||||||||
| Increase Decrease In Accounts Payable | $267.0K | $829.0K | -$1.3M | -$7.0K | -$644.0K | $15.0K | ||||||||||||
| Increase Decrease In Accounts And Other Receivables | -$55.0K | $67.0K | -$122.0K | $41.0K | -$420.0K | $210.0K | ||||||||||||
| Payments To Acquire Intangible Assets | $123.0K | $31.0K | $73.0K | $71.0K | $10.0K | |||||||||||||
| Net Cash Provided By Used In Investing Activities | -$150.0K | $14.0K | $346.0K | $767.0K | -$140.0K | |||||||||||||
| Payments To Acquire Property Plant And Equipment | $27.0K | $16.0K | $42.0K | $47.0K | $130.0K | |||||||||||||
| Increase Decrease In Other Operating Assets | -$1.0K | -$3.0K | $2.0K | $57.0K | -$24.0K | |||||||||||||
| Stock Issued During Period Value Share Based Compensation | $448.0K | $1.4M | $499.0K | $699.0K | $421.0K | $505.0K | $865.0K | $491.0K | $2.5M | $2.2M | $1.3M | $13.0K | $11.0K | |||||
| Share Based Compensation | $340.0K | $295.0K | $421.0K | $1.3M | $13.0K | |||||||||||||
| Employee Benefits And Share Based Compensation | $421.0K | $505.0K | $865.0K | $491.0K | $2.5M | $2.2M | $1.3M | |||||||||||
| Payments Of Stock Issuance Costs | $856.0K | $919.0K | $1.1M | $3.0M | ||||||||||||||
| Depreciation Amortization And Accretion Net | $238.0K | $188.0K | $195.0K | $195.0K | ||||||||||||||
| Increase Decrease In Deferred Revenue | $39.0K | $320.0K | $50.0K | $306.0K | $375.0K | |||||||||||||
| Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition | $513.0K | $340.0K | $1.4M | $230.0K | $295.0K | $499.0K | $699.0K | $421.0K | ||||||||||
| Proceeds From Issuance Of Common Stock | $100.0K | $26.7M | ||||||||||||||||
| Payments Related To Tax Withholding For Share Based Compensation | $37.0K | $17.0K | $141.0K | |||||||||||||||
| Increase Decrease In Other Operating Capital Net | $64.0K | $63.0K | $76.0K | |||||||||||||||
| Proceeds From Sale And Maturity Of Marketable Securities | $61.0K | $461.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.29 | -$2.62 | -$10.22 | -$0.90 | -$0.90 | -$0.23 |
| Weighted Average Number Of Shares Outstanding Basic | 17.58B | 9.41B | 2.17B | 21.0M | 18.9M | |
| Weighted Average Number Of Diluted Shares Outstanding | 17.58B | 9.41B | 2.17B | 21.0M | 18.9M | |
| Earnings Per Share Basic | $-1.29 | $-2.62 | $-10.22 | $-0.90 | $-0.90 | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Preferred Stock Shares Authorized | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.39 | -$0.33 | -$0.34 | -$0.34 | -$1.83 | -$1.61 | -$2.79 | -$2.67 | -$2.21 | -$0.25 | -$0.27 | -$0.17 | -$0.25 | -$0.26 | -$0.18 | -$0.06 | -$0.08 |
| Weighted Average Number Of Shares Outstanding Basic | 18.37B | 15.01B | 14.95B | 13.63B | 6.51B | 2.51B | 2.12B | 2.1M | 2.1M | 21.0M | 20.9M | 20.9M | 19.1M | 19.0M | |||
| Weighted Average Number Of Diluted Shares Outstanding | 18.37B | 15.01B | 14.95B | 13.63B | 6.51B | 2.51B | 2.12B | 2.1M | 2.1M | 21.0M | 20.9M | 20.9M | 19.1M | 19.0M | |||
| Earnings Per Share Basic | $-0.39 | $-0.33 | $-0.34 | $-0.34 | $-1.83 | $-1.61 | $-2.79 | $-2.67 | $-2.21 | $-0.25 | $-0.27 | $-0.17 | $-0.25 | $-0.26 | |||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Preferred Stock Shares Authorized | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M | ||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Additional Paid In Capital | $138.0M | $131.5M | $91.8M | $83.7M | $81.5M | |
| Other Income | $300.0K | $57.0K | $64.0K | |||
| Stock Issued During Period Value New Issues | $5.0M | $12.9M | -$304.0K | -$452.0K | $1.1M | |
| Grant Income | $282.0K | $598.0K | $4.3M | |||
| Clinical Trial Income | $708.0K | $1.3M | ||||
| Depreciation And Amortization | $1.2M | $958.0K | $946.0K | $893.0K | ||
| Stock Issued During Period Unrealized Loss Attributable To Change In Market Value Of Available For Sale Securities | $357.0K | -$357.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional Paid In Capital | $136.8M | $132.3M | $131.8M | $131.1M | $115.9M | $92.1M | $86.0M | $84.7M | $84.1M | $83.0M | $82.5M | $81.8M | $62.3M | $59.7M | $56.6M | |||
| Other Income | $55.0K | $80.0K | $69.0K | -$57.0K | -$5.0K | -$116.0K | $51.0K | $54.0K | $47.0K | $24.0K | $10.0K | |||||||
| Stock Issued During Period Value New Issues | $4.1M | $8.1M | $4.7M | -$86.0K | -$17.0K | -$27.0K | -$166.0K | -$128.0K | ||||||||||
| Grant Income | $55.0K | $126.0K | $60.0K | $68.0K | $275.0K | $211.0K | $1.8M | $868.0K | $946.0K | |||||||||
| Clinical Trial Income | $210.0K | $340.0K | $310.0K | $164.0K | $214.0K | $165.0K | $30.0K | $762.0K | ||||||||||
| Depreciation And Amortization | $421.0K | $252.0K | $238.0K | |||||||||||||||
| Stock Issued During Period Unrealized Loss Attributable To Change In Market Value Of Available For Sale Securities | -$2.0K | $1.0K | $26.0K | -$36.0K | $58.0K |
Most recent annual filing with the SEC: March 17, 2026
Data sourced from SEC EDGAR public filings as of August 8, 2026.